soul trial oral semaglutide cardiovascular outcomes 2024 results nejm and in Type 2 Diabetes Cardiovascular risk reduction with once-weekly

doi:10.1111/dom.13129 Duchemin L, Morice A, Bernardeau C, et al

The clinical advantage is concrete: subcutaneous administration takes approximately 30 minutes, compared to 30 to 60 minutes for IV infusion, reducing chair time in infusion centers and potentially enabling administration in less-equipped settings

Injection Site Reactions Common side effects include temporary redness, swelling, or a slight pinch sensation at the injection site

A 2023 systematic review that pooled roughly 10 studies with nearly 10,000 participants found that people taking tirzepatide lost about 22 pounds more than those on a placebo

The peptide safety and risks guide provides a thorough overview of what is known and where knowledge gaps remain

You can choose one as per your taste and preference